Skin wound healing promoters
AssigneesSanten Pharmacetical Co., Ltd., Teruo Nishida
InventorsTeruo Nishida, Katsuhiko Nakata, Masatsugu Nakamura
Life of this patent
Estimating the term…
Abstract
The present invention provides healing promoters for skin wounds such as rupture, abrasion, surgical incision, skin ulcer and burn. Coexistence of Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO: 1) or Phe-Gly-Leu-Met-NH2 (SEQ ID NO: 2) with insulin-like growth factor-I exhibits a remarkable promotive action on healing the skin wounds. Accordingly, combined administration of at least one of the substance P analogs and pharmaceutically acceptable salts thereof with the insulin-like growth factor exhibits a promotive effect on epidermal extension and a promotive effect on healing the skin wounds.
Claims12
A method of treating a wound to a surface tissue, wherein the surface tissue consists of skin, comprising administering to a patient in need thereof a composition comprising effective amounts for treatment of a substance P analog which is Phe-Gly-Leu-Met-NH2 (SEQ ID NO:
- 2) as a unit or a pharmaceutically acceptable salt thereof, and insulin-like growth factor-I, as active ingredients.
A method of treating a wound to a surface tissue, wherein the surface tissue consists of skin, comprising administering to a patient in need thereof a composition comprising 0.001 to 10% by weight of a substance P analog which is Phe-Gly-Leu-Met-NH2 (SEQ ID NO:
- 2) as a unit or a pharmaceutically acceptable salt thereof and 0.0001 to 5% by weight of insulin-like growth factor-I, as active ingredients.
Dependencies are inferred from the claim text.